StemCell Institute (7096) · InitiativeAchieved
Lowering the investment unit and improving liquidity through a stock split
First written in FY2023-Q2. 1 of 2 entries say "Achieved", first in FY2023-Q3. Latest entry: FY2023-Q3.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Stock SplitA theme 990 companies write about · 0 as a headwind · 979 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 197 companies compared. The sentences above are computed from all 197.Comparing 200 of the theme's 1001 threads.Full recordFilings, disclosures and news, newest first
- FY2023-Q3AchievedAnnual report
「Effective 1 January 2023, the Company conducted a 2-for-1 split of its common shares. As a result, the number of shares outstanding increased by 5,123,300 to 10,246,600.」
The planned 2-for-1 stock split was implemented effective 1 January 2023, bringing the number of shares outstanding to 10,246,600. - FY2023-Q2First statedAnnual report
「The purpose is to improve the liquidity of our shares and broaden the investor base by increasing the number of shares outstanding through a stock split and lowering the investment amount per unit.」
At a meeting of the Board of Directors held on 8 November 2022, the Company resolved to conduct a 2-for-1 split of its common shares, with 31 December 2022 as the record date and 1 January 2023 as the effective date. The number of shares outstanding after the split was planned to be 10,246,600.